You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

VIIBRYD Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Viibryd patents expire, and when can generic versions of Viibryd launch?

Viibryd is a drug marketed by Abbvie and is included in one NDA.

The generic ingredient in VIIBRYD is vilazodone hydrochloride. There are fourteen drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the vilazodone hydrochloride profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Viibryd

A generic version of VIIBRYD was approved as vilazodone hydrochloride by TEVA PHARMS USA on September 30th, 2019.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for VIIBRYD?
  • What are the global sales for VIIBRYD?
  • What is Average Wholesale Price for VIIBRYD?
Drug patent expirations by year for VIIBRYD
Drug Prices for VIIBRYD

See drug prices for VIIBRYD

Drug Sales Revenue Trends for VIIBRYD

See drug sales revenues for VIIBRYD

Recent Clinical Trials for VIIBRYD

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Forest LaboratoriesPhase 1
New York State Psychiatric InstitutePhase 4
Forest LaboratoriesPhase 3

See all VIIBRYD clinical trials

Paragraph IV (Patent) Challenges for VIIBRYD
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
VIIBRYD Tablets vilazodone hydrochloride 10 mg, 20 mg, and 40 mg 022567 5 2015-01-21

US Patents and Regulatory Information for VIIBRYD

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie VIIBRYD vilazodone hydrochloride TABLET;ORAL 022567-001 Jan 21, 2011 AB RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Abbvie VIIBRYD vilazodone hydrochloride TABLET;ORAL 022567-002 Jan 21, 2011 AB RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Abbvie VIIBRYD vilazodone hydrochloride TABLET;ORAL 022567-003 Jan 21, 2011 AB RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for VIIBRYD

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie VIIBRYD vilazodone hydrochloride TABLET;ORAL 022567-001 Jan 21, 2011 ⤷  Sign Up ⤷  Sign Up
Abbvie VIIBRYD vilazodone hydrochloride TABLET;ORAL 022567-003 Jan 21, 2011 ⤷  Sign Up ⤷  Sign Up
Abbvie VIIBRYD vilazodone hydrochloride TABLET;ORAL 022567-002 Jan 21, 2011 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for VIIBRYD

See the table below for patents covering VIIBRYD around the world.

Country Patent Number Title Estimated Expiration
Japan 2010132688 POLYMORPHIC FORM OF 1-4-(5-CYANOINDOL-3-YL)BUTYL-4-(2-CARBAMOYLBENZOFURAN-5-YL)PIPERAZINE HYDROCHLORIDE ⤷  Sign Up
South Korea 20040012922 ⤷  Sign Up
Hungary 0400236 ⤷  Sign Up
Germany 4333254 ⤷  Sign Up
Canada 2782517 ⤷  Sign Up
Australia 2002320822 ⤷  Sign Up
Ecuador SP044943 FORMAS POLIMORFICAS DEL CLORHIDRATO DE 1-[4-5(5-CIANOINDOL-3-IL)BUTIL]-4-(2-CARBAMOILBENZOFURAN-5-IL)PIPERAZINA ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.